This study is being done to answer the following questions:
- Is the new drug, RP-6306, safe to use, and what effects does it have on cancer when
given with standard treatment?
- If there are specific biomarkers, do patients have an improved response to treatment
compared to those without the biomarker?
This study is being done to find out if this approach is better or worse than the usual
approach for this type of cancer. The usual approach is defined as care most people get for
this type of cancer.